US FDA's New Paragraph IV Data Further Illustrates Generic Competition Problems
Executive Summary
Data on the number of ANDAs submitted with valid paragraph IV certifications shows some products with strong generic interest and others with almost none.
You may also be interested in...
House Vs. Senate Drug Pricing Bills: A Snapshot Of Differences
Senate and House will likely have to reconcile differences on drug pricing legislation as Senate HELP Committee seeks public comment on a discussion draft.
Complex Generic Mid-Cycle Meetings: US FDA Suggests Taking The Date Offered
US FDA offers best practices and tips to ensure successful meetings, although few have been conducted so far.
Generic Industry Market Forces May Impact GDUFA III Talks
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.